Long-term safety study of valbenazine for Huntington's chorea in Canada
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Mental health clinical trials.
This study is for people in Canada who have already been taking valbenazine for Huntington's chorea in a previous study (NBI-98854-HD3006). It tests the long-term safety of the medicine and continues for up to 156 weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken part in the previous study NBI-98854-HD3006 and finished the full 156 weeks of treatment, or have been in that study when it ended in Canada.
- If you could become pregnant, you must use birth control during the study and for 30 days after your last dose.
- You must not have trouble swallowing.
- You must not be pregnant or breastfeeding.
- You must not have any serious medical problem or abnormal lab test results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if valbenazine helps adults with tardive dyskinesia whose symptoms continue even after taking or stopping another similar medication. Tardive dyskinesia involves uncontrollable movements from long-term use of certain mental health drugs.
This is an early-phase study testing a new drug (RG6496) for people with Huntington's disease. The study will check the drug's safety and how the body processes it, and it requires two doses given about 6 months apart.
This Phase 2 study tests whether valbenazine can reduce symptoms of trichotillomania (a hair-pulling disorder) in adults. You may be able to join if your symptoms cause major distress or interfere with daily life.
This early-phase study tests whether VO659 is safe and how the body processes it in people with certain genetic movement disorders (SCA1, SCA3, or Huntington disease). It may help researchers learn the right dose and whether the drug can be given safely.
This study checks the long-term safety of BHV-7000 for people who already completed an earlier trial with this drug. You keep taking the same medicine while doctors watch for any side effects over time.
This Phase 2 study tests whether NAC (a supplement-like medicine) can delay symptoms in people who carry the Huntington’s disease gene expansion but do not yet have clear movement symptoms. You may be asked to take NAC and attend regular visits, scans, and blood tests to see if it changes how likely you are to develop Huntington’s disease within the next 10 years.
Hear when a new Chorea, Huntington trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.